Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNYZ) Long-Term Debt Repayments (2018 - 2023)

Historic Long-Term Debt Repayments for Ligand Pharmaceuticals (LGNYZ) over the last 10 years, with Q2 2023 value amounting to $76.9 million.

  • Ligand Pharmaceuticals' Long-Term Debt Repayments rose 2820.32% to $76.9 million in Q2 2023 from the same period last year, while for Sep 2024 it was $76.9 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $76.9 million for FY2023, which is 7054.83% down from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Long-Term Debt Repayments stood at $76.9 million for Q2 2023, which was up 2820.32% from $37.6 million recorded in Q3 2022.
  • Ligand Pharmaceuticals' 5-year Long-Term Debt Repayments high stood at $203.2 million for Q1 2020, and its period low was $2.4 million during Q3 2021.
  • Over the past 5 years, Ligand Pharmaceuticals' median Long-Term Debt Repayments value was $52.3 million (recorded in 2021), while the average stood at $74.3 million.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first crashed by 4644.85% in 2021, then skyrocketed by 148242.96% in 2022.
  • Ligand Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $27.3 million in 2019, then plummeted by 30.47% to $19.0 million in 2020, then plummeted by 87.48% to $2.4 million in 2021, then surged by 1482.43% to $37.6 million in 2022, then skyrocketed by 104.15% to $76.9 million in 2023.
  • Its Long-Term Debt Repayments stands at $76.9 million for Q2 2023, versus $37.6 million for Q3 2022 and $59.9 million for Q2 2022.